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message is that agents considered as either biosimilars or
follow-on biologics should be regarded as essentially
different from the innovator biologic by virtue of subtle
differences in the manufacturing and/or purification
process. These agents must undergo formal regulatory
approval and they should be marketed in the context of a
strong pharmacovigilance infrastructure. In this regard,
the EMEA has provided a well-thought-out process for
regulatory approval, and the European Union, like the
United States, has robust pharmacovigilance in place.
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To the Editor: We read with interest the stimulating article
by Ahmed et al.1 on the association of oral hormone
replacement therapy and kidney function in postmenopausal
women.
The authors reported the baseline characteristics of the
groups by categorical hormone therapy use. There was a
significant difference in terms of the use of nonsteroidal anti-
inflammatory drugs and diuretics. The groups namely
‘Estrogen only’ (46.8%) and ‘Progestin only’ (52.5%) had a
higher percentage of patients on diuretics. The percentage of
patients on nonsteroidal anti-inflammatory drugs was higher
(45.3%) in the ‘Estrogen only’ group. The elderly (all 66 years
old or older) made up the entire data population. This makes
the subjects more vulnerable to the effects of both
nonsteroidal anti-inflammatory drugs and diuretics on the
renal function. Although other factors were analyzed in
multivariate analysis, we are surprised that the authors did
not include diuretics in the analysis. These drugs are known
to affect effective circulating volume and renal function.2,3
Logistic regression analysis has shown the greatest decline
of glomerular filtration rate in the ‘Progestin only’ group
(D, 3.98; confidence interval: 0.30, 8.26) followed by the
‘Estrogen only’ group (D, 1.21; confidence interval: 0.28,
2.14), but the ‘Combined group’ had the least decline in
glomerular filtration rate (D, 0.99; confidence interval: 0.56,
2.54) with large confidence intervals.1 They did not offer a
plausible explanation for this discrepancy. We hope that they
have a reasonable explanation for this, or is this just a
statistical finding? It will be interesting to see their results
with the inclusion of diuretic use in the analysis.
1. Ahmed SB, Culleton BF, Tonelli M et al. Oral estrogen therapy in
postmenopausal women is associated with loss of kidney function. Kidney
Int 2008; 74: 370–376.
2. Hawkins RG, Houston MC. Is population-wide diuretic use directly
associated with the incidence of end-stage renal disease in the United
States? AJH 2005; 18: 744–749.
3. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat
Clin Pract Nephrol 2006; 2: 80–91.
Aniruddha V. Palya1, Bulent Cuhaci1 and Karthik M. Ranganna1
1Division of Nephrology, Drexel University College of Medicine, Philadelphia,
Pennsylvania, USA
Correspondence: Aniruddha V. Palya, Division of Nephrology, Drexel
University College of Medicine, 245 N. 15th Street, 6th Floor, suite 6109,
Mailstop 437, Philadelphia, Pennsylvania 19102, USA.
E-mail: Aniruddha.Palya@DrexelMed.edu
442 Kidney International (2009) 75, 440–442
l e t t e r t o t h e e d i t o r
